Form 10-K Mersana Therapeutics, For: Dec 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
- AMD shares fall amid AI chip sector selloff
- JetBlue shares fall amid American results, fuel cost concerns
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- LKQ posts Q3 loss, replaces CEO amid Europe struggles
BTIG Upgrades Mersana (MRSN) to Buy
February 28, 2024 3:38 PM ESTBTIG analyst Kaveri Pohlman upgraded Mersana (NASDAQ: MRSN) from Neutral to Buy with a price target of $6.00.
The analyst comments "We believe that the upcoming catalysts this year could significantly de-risk the Dolasynthen platform and the lead ADC, XMT-1660 (B7-H4 Dolalock ADC),... More



